secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0000950103-21-017355
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen reports Phase 1 data: 50% AML ORR, 40% HPV ORR; cash $181.3M
---------------------------------------------------------------------

- 50% ORR (3/6) in relapsed/refractory AML at low dose levels of PRGN-3006 UltraCAR-T in Phase 1 lymphodepletion cohort.
- 40% ORR (2/5) and 60% DCR (3/5) in recurrent/metastatic HPV-associated cancer with PRGN-2009 AdenoVerse combination arm.
- PRGN-3006 and PRGN-3005 show no dose-limiting toxicities or neurotoxicity; durable expansion and persistence observed.
- Cash, equivalents, and investments totaled $181.3M at Sep 30, 2021; net cash used in ops $41.2M (9 months, vs $60.6M prior year).
- PRGN-3006 abstract selected for oral presentation at 63rd ASH Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010321017355/0000950103-21-017355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010321017355/dp161305_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-21-017355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer